An investment consortium is aiming to create “a top-10 Russian pharmaceutical company”, operating in the non-state sector, by combining its acquisition of local player OBL Pharm with its existing control of Binnopharm. Through their joint holding company Ristango Holding, conglomerate Sistema, VTB Bank and OBL’s management team have paid RUB15.5 billion (US$225 million) to acquire a 95.14% stake in OBL from Gazprombank and UFG private equity’s Alvansa vehicle.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?